Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

“Lung cancer is a disease where uncontrolled cell growth occurs in the lung leading to tumours,” explains Dr Jenny Messenger, ...

A new "liquid biopsy" test can help fast-track lung cancer patients to receive targeted therapy up to two weeks earlier, ...

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.

A new blood test will be offered to lung cancer patients in a move that NHS England says will benefit about 15,000 people ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

A recently-approved treatment could take a BiTE out of small cell lung cancer by using a person's own body to fight back.

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...